United States: Wilmerhale Represents Curis In $45M Debt Transaction With Healthcare Royalty Partners
Last Updated: April 6 2017

Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, announced a $45 million debt transaction with HealthCare Royalty Partners. The deal is meant to help fund an oncology pipeline for Curis.

The WilmerHale deal team that represented Curis included John Sigel and Eric French.

For more information read Curis' Fourth Quarter and Year-End Financial Results press release.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Geoffroy Barthet, Nicole Callan, Cormac O'Daly, Hartmut Schneider
By WilmerHale
By WilmerHale
By Alan Wilson, Jonathan Wolfman
By WilmerHale
By Anna Gaudoin
By Rachel Jacobson, Nathaniel Custer, Mark Hanin
By Leila Gaafar
By Paul M. Architzel, Anjan Sahni, Matthew Beville, Daniel Martin
By Glenn Luinenburg
Tools
Print
Font Size:
Translation
Channels